|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.10/-2.74
|
Enterprise Value
1.68B
|
Balance Sheet |
Book Value Per Share
7.18
|
Cash Flow |
Cash Flow Yield
0.01
|
Income Statement |
Total Revenue
249.43M
|
Operating Revenue Per Share
0.83
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 19:27 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. |